Multiple myeloma is entering an era of unprecedented therapeutic choice—and equally unprecedented uncertainty. A new clinical perspective by C.R. Tan and S. Mailankody, published in Nature Reviews Clinical Oncology, examines the rapidly expanding treatment landscape for patients whose disease returns early after initial therapy or fails to respond at all. The article, titled “More options, more questions in the management of early relapsed and/or refractory multiple myeloma,” highlights a central challenge in modern cancer care: having more treatments does not automatically make the best treatment easier to identify.
Multiple myeloma is a blood cancer that develops when abnormal plasma cells accumulate in the bone marrow and produce excessive amounts of a single antibody or antibody fragment. These malignant cells can interfere with normal blood-cell production and damage bones, kidneys and the immune system. Although the disease is often controllable for extended periods, it remains difficult to cure. Relapse occurs when myeloma returns after treatment, while refractory disease refers to cancer that does not respond adequately or progresses despite therapy. When relapse happens soon after initial treatment, the disease may be biologically aggressive and less sensitive to previously used drugs.
For years, treatment decisions after relapse were guided largely by which medicines a patient had already received and how long the response had lasted. That framework is becoming harder to apply as the therapeutic arsenal expands. Modern myeloma care may involve combinations built around proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies directed against proteins such as CD38. Newer immune-based approaches, including chimeric antigen receptor T-cell therapy and bispecific antibodies, have added powerful tools capable of directing the immune system toward malignant plasma cells.
The technological leap is substantial. CAR-T therapy removes a patient’s T cells, genetically modifies them in the laboratory so they can recognize a myeloma-associated target, expands them and returns them to the bloodstream. Bispecific antibodies work differently: they act as molecular bridges, binding both a cancer-cell target and a protein on T cells. This physical connection can activate immune cells against myeloma. Both strategies can produce deep responses, but they also bring complex challenges involving manufacturing time, treatment access, immune-related complications, infections and the possibility that cancer cells may change or lose the targeted protein.
The timing of these treatments has become one of the most important questions in the field. Should cellular therapies and bispecific antibodies be reserved for patients who have exhausted several earlier options, or should they move closer to the beginning of the treatment sequence? The answer may not be identical for every patient. Earlier use could expose aggressive disease to highly active therapy before additional resistance develops, potentially improving disease control. On the other hand, deploying advanced treatments too soon may reduce future options, create avoidable toxicity or place significant pressure on healthcare systems.
Early relapse is particularly important because it may signal a form of myeloma with high-risk biological features. Cancer cells that survive initial treatment are not necessarily representative of the original tumor. They may carry genetic changes that allow them to evade drugs, repair cellular damage more efficiently or resist immune attack. This evolutionary process means that relapse is not simply a return of the same disease; it can be a transformed population of malignant cells with new vulnerabilities and new defenses. Understanding that biology could help clinicians select treatments more rationally instead of relying only on treatment history.
The review also reflects a broader shift toward individualized decision-making. A patient’s age, kidney function, previous therapies, residual side effects, disease genetics, infection risk and ability to travel for specialized treatment can all influence the practical value of a therapy. A treatment that produces impressive results in a clinical trial may be difficult to deliver to someone who needs urgent disease control or who lacks access to a center capable of providing cell therapy. Real-world effectiveness therefore depends not only on drug activity, but also on logistics, timing and the patient’s overall condition.
Another unresolved issue is how best to compare increasingly different treatment strategies. Traditional clinical trials often evaluate one regimen against another using measures such as progression-free survival, overall survival and response depth. Yet advanced immune therapies raise additional questions. A delayed response may still become durable. A small amount of detectable disease may have a different meaning after an immune-based treatment than after conventional chemotherapy. Minimal residual disease testing, which searches for tiny populations of cancer cells left after treatment, could become increasingly important, but its role in guiding treatment duration and sequencing is still being defined.
The expanding menu of therapies also intensifies the need for better biomarkers. Researchers are seeking molecular and immune features that can predict who will respond to a particular target, who is likely to experience severe toxicity and which patients may benefit from combination or sequential approaches. Without such tools, treatment selection can become a process of trial and error, especially for patients whose disease progresses rapidly. The questions raised by Tan and Mailankody therefore extend beyond choosing the next drug: they concern how to build a treatment strategy across the entire course of an evolving cancer.
The message emerging from this changing landscape is both encouraging and cautionary. Patients with early relapsed or refractory multiple myeloma have more scientifically sophisticated options than ever before, including therapies that can generate remarkably deep responses. Yet the arrival of each new option creates further questions about optimal timing, sequencing, resistance, safety, cost and equitable access. The future of myeloma treatment may depend less on discovering a single universally superior therapy than on learning how to match the right intervention to the right disease state at the right moment.
Subject of Research: Early relapsed and/or refractory multiple myeloma
Article Title: More options, more questions in the management of early relapsed and/or refractory multiple myeloma
Article References: Tan, C.R., Mailankody, S. “More options, more questions in the management of early relapsed and/or refractory multiple myeloma.” Nature Reviews Clinical Oncology (2026). https://doi.org/10.1038/s41571-026-01191-6
Image Credits: AI Generated
DOI: 10.1038/s41571-026-01191-6
Keywords: Multiple myeloma, early relapse, refractory disease, CAR-T therapy, bispecific antibodies, immunotherapy, cancer treatment, treatment sequencing, precision oncology
